Valuation: BioCryst Pharmaceuticals, Inc.

Market Cap 2.72B 2.38B 2.2B 2.03B 3.85B 260B 3.92B 26.26B 10.31B 128B 10.23B 10.01B 440B P/E 2026 *
-4.1x
P/E 2027 * 19.9x
Enterprise Value 2.72B 2.38B 2.2B 2.03B 3.85B 260B 3.92B 26.26B 10.31B 128B 10.23B 10.01B 440B EV / Sales 2026 *
4.06x
EV / Sales 2027 * 3.75x
Free-Float
94.36%
Yield 2026 *
-
Yield 2027 * -
Jul. 07 RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating MT
Jun. 29 BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs RE
Jun. 29 BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End MT
Jun. 29 BioCryst Pharmaceuticals, Inc. Discontinues Internal Discovery Programs And Closes Birmingham Research Facility CI
Jun. 29 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Benchmark CI
Jun. 28 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000E Value Benchmark CI
Jun. 28 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000 Value Benchmark CI
Jun. 28 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Benchmark CI
Jun. 28 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2500 Value Benchmark CI
Jun. 12 BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment MT
Jun. 12 BioCryst Pharmaceuticals Presents New Clinical Data and Real-World Evidence for HAE Portfolio at the European Academy of Allergy and Clinical Immunology Annual Meeting CI
May. 27 BioCryst Pharmaceuticals Presents New HAE Data From ORLADEYO And Navenibart At The European Academy Of Allergy And Clinical Immunology Annual Meeting CI
May. 12 BioCryst Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 01:40 PM
1 day-2.94%
1 week+2.41%
Current month+4.15%
1 month+27.17%
3 months+8.94%
6 months+46.90%
Current year+33.53%
1 week 9.71
Extreme 9.71
11.22
1 month 8.1
Extreme 8.1
11.22
Current year 6.23
Extreme 6.23
11.22
1 year 6
Extreme 6
11.22
3 years 4.03
Extreme 4.03
11.31
5 years 4.03
Extreme 4.03
19.99
10 years 1.38
Extreme 1.38
19.99
Manager TitleAgeSince
Chief Executive Officer 55 2025-12-31
Director of Finance/CFO 47 2025-07-06
Chief Tech/Sci/R&D Officer 51 2026-04-05
Director TitleAgeSince
Director/Board Member 65 2006-12-31
Director/Board Member 64 2018-12-02
Director/Board Member 55 2025-12-31
Date Insider Type Main position Quantity % Market Cap.
Jun. 10Free

Director

48,834 0.0192%
Jun. 10Free

Director

48,834 0.0192%
Jun. 10Free

Director

48,834 0.0192%
Change 5-day change 1-year change 3-year change Capi.($)
-2.85%+2.41%+17.29%+41.32% 2.72B
-4.14%-7.44%+64.26%+119.36% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-2.67%+2.91%+18.76%+462.70% 25.63B
-1.41%-2.49%-19.60%-14.74% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-0.73%+2.02%+25.42%+197.07% 14.35B
Average -0.99%+0.84%+51.43%+135.89% 24.49B
Weighted average by Cap. -1.13%-0.76%+56.14%+137.06%

Financials

2026 *2027 *
Net sales 671M 587M 541M 500M 949M 64B 965M 6.47B 2.54B 31.53B 2.52B 2.46B 108B 727M 636M 587M 542M 1.03B 69.36B 1.05B 7.01B 2.75B 34.17B 2.73B 2.67B 117B
Net income -645M -564M -520M -480M -911M -61.47B -927M -6.21B -2.44B -30.28B -2.42B -2.37B -104B 144M 126M 116M 107M 203M 13.69B 206M 1.38B 543M 6.74B 539M 527M 23.19B
Net Debt - -
Logo BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.
Employees
435
Date Price Change Volume
26-07-10 $10.42 -2.85% 2,056,277
26-07-09 $10.72 -3.51% 3,982,332
26-07-08 $11.11 +1.09% 7,429,410
26-07-07 $10.99 +8.06% 10,280,196
26-07-06 $10.17 +3.35% 4,380,034
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
10.72USD
Average target price
21.90USD
Spread / Average Target
+104.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCRX Stock